China chip stocks rally on self-reliance bets, Nvidia scrutiny
Lucid (NASDAQ:LCID) Diagnostics Inc. (LUCD) shares soared to a 52-week high of $1.5, marking a remarkable 27.1% gain in the past week and 64.9% over six months. This surge has pushed the $75 million market cap company's valuation above InvestingPro's Fair Value estimate, while analyst price targets range from $2 to $7. This milestone reflects a significant turnaround from previous performance, with the stock demonstrating an 8.76% increase over the past year, supported by impressive revenue growth of 179% in the last twelve months. The ascent to this new high suggests that market participants are increasingly optimistic about Lucid Diagnostics' strategic initiatives and potential for expansion in its market segment. Investors are closely monitoring the company's progress as it capitalizes on this positive momentum. InvestingPro subscribers have access to 14 additional exclusive insights about LUCD's financial health and growth prospects.
In other recent news, Lucid Diagnostics faced a reduction in its stock target by Cantor Fitzgerald due to challenges in obtaining broader reimbursement for its services. Despite the lowered target, the firm continues to recommend the stock with an Overweight rating. The new target figure was calculated using a combination of discounted cash flow (DCF) analysis and an enterprise value to calendar year 2025 estimated revenue (EV/CY25E) multiple, which was increased to 6.0x from the previous 3.0x. This premium was justified by Lucid's superior growth rate and its unique product offering. The DCF analysis was probability-adjusted with a 75% chance of success and a 15% discount rate. The total equity value of Lucid Diagnostics was estimated to be around $116 million, which equates to approximately $2.07 per share. This figure, when averaged with the share price implied by the peer revenue multiple of $1.67, resulted in the new $2.00 price target. These are the latest developments in the ongoing analysis of Lucid Diagnostics' financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.